Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3702590 | 1.00 | CYP2D6 (0.41) | CYP2D6ADRA2AADRA1APDE2AMEN1 | |
| SCHEMBL30949362 | 1.00 | CYP2D6 (0.41) | CYP2D6ADRA2AADRA1APDE2AMEN1 | |
| SCHEMBL25180793 | 1.00 | CYP2D6 (0.41) | CYP2D6ADRA2AADRA1APDE2AMEN1 | |
| SCHEMBL30166162 | 1.00 | CYP2D6 (0.41) | CYP2D6ADRA2AADRA1APDE2AMEN1 | |
| SCHEMBL669891 | 0.85 | CYP2D6 (0.49) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL895659 | 0.85 | CYP2D6 (0.49) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL896090 | 0.85 | CYP2D6 (0.49) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL29429683 | 0.85 | CYP2D6 (0.49) | CYP2D6ADRA2AADRA1AMEN1MAPK1 | |
| SCHEMBL765434 | 0.84 | GAA (0.43) | MEN1KMT2AKDM4E | |
| SCHEMBL12563123 | 0.82 | KDM4E (0.39) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118164989-A | Imidazo [1,2-b ] pyridazine derivatives as TRK inhibitors and application thereof | 上海医药工业研究院有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-18 | — | — | US | disclosed |
| US-8008487-B2 | Substituted thieno[2,3-D]pyrimidines as fungicides | DOW AGROSCIENCES LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008487-B2 | Substituted thieno[2,3-D]pyrimidines as fungicides | DOW AGROSCIENCES LLC (US) | 2011-08-30 | — | — | US | disclosed |
| WO-2010136037-A1 | NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150981-A1 | N-HETEROARYLALKYL-2-(HETEROCYCLYL AND HETEROCYCLYLMETHYL) ACETAMIDE DERIVATIVES AS SSTR4 AGONISTS | SSTR4, SSTR3, SSTR5 | CYP2D6 1497/4885ADRA2A 169/4885ADRA1A 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.